A Bengaluru startup that uses artificial intelligence to redesign how pharmaceutical and electronic chemicals are manufactured has raised ₹36.5 crore, roughly $4 million, in a seed round announced October 13, 2026. NuSynth Technologies, co-founded by a former pharma CEO and three scientists, secured backing from Avaana Capital and Shastra VC with an audacious pitch: software can rewrite the recipes for high-value chemicals, cutting both costs and India's $4.35 billion import bill for active pharmaceutical ingredients and intermediates in FY2024–25.
The company's premise touches a nerve in Indian industrial policy. For decades, the country has relied heavily on imports for bulk drugs and specialty chemicals, particularly from China. Now, NuSynth is wagering that machine learning can unlock shorter, cleaner synthesis routes, helping India manufacture more of what it currently buys abroad.
"We believe the next chapter will be defined by our ability to innovate on the underlying chemistry itself," Poorvank Purohit, NuSynth's co-founder and CEO, told Business Standard. Purohit knows the terrain: he served as managing director and CEO of Solara Active Pharma Sciences starting in mid-2023. His co-founders bring a different kind of credibility. Dr. Ramesha A R, a postdoctoral researcher at the National Institutes of Health with a doctorate from the Indian Institute of Science, anchors the scientific team, along with Abhishek Deo and Dipak Bajaj.
Redesigning Synthesis from First Principles
Chemical synthesis for high-value pharmaceuticals and electronics has long been a stubborn puzzle. Traditional routes often involve six to twelve steps, each draining yield and piling up hazardous solvents. For India's specialty chemicals sector, which industry analysts expect to grow 7–8 percent in revenue over the next fiscal years, the inefficiency is both a cost burden and an environmental liability.
NuSynth's platform uses AI to rethink these processes from the ground up, according to Avaana Capital's portfolio page. The goal: fewer steps, elimination of toxic reagents, lower temperatures, reduced solvent loads, less waste. The startup operates a lab and pilot plant in Mysuru, with a second R&D facility under development in Bengaluru. According to its LinkedIn profile, the company lists between 11 and 50 employees and claims partnerships with more than 20 verified contract manufacturers across India.
Shruti Srivastava, a partner at Avaana Capital, said the approach "will improve the economics, resource efficiency and resilience of chemical manufacturing across critical sectors." Avijeet Alagathi, managing partner at Shastra VC, framed the investment in global terms, noting that "data and an AI engine [position] NuSynth to build a differentiated process innovation platform from India for global markets."
The seed capital will fund expansion of NuSynth's R&D and technology stack, development of proprietary process intellectual property, scale-up capability, and hiring.
India's Import Substitution Push
The stakes are national as well as commercial. The Indian government has reported imports of approximately 200 categories of APIs, bulk drugs, and intermediates worth billions of dollars in recent fiscal years, according to official data. The country's Production Linked Incentive scheme for bulk drugs has mobilized significant investments and created tens of thousands of metric tons per year of capacity across more than two dozen critical products, the Economic Survey noted.
Electronic chemicals present a parallel opportunity. India's semiconductor chemicals market has been sized in the hundreds of millions of dollars, with projections suggesting it could more than double over the next several years, according to market research firms. Micron recently opened India's first semiconductor assembly and test facility in Sanand, Gujarat, and the Semicon India 2.0 initiative has attracted multi-billion-dollar proposals.
The policy backdrop is clear: India wants to manufacture more at home. Whether NuSynth's AI-driven approach can actually deliver on that ambition remains an open question.
Asset-Light Scale Through Partners
NuSynth is not building its own manufacturing plants, a deliberate choice that mirrors tactics employed by specialty chemicals startups elsewhere. The company is commercializing redesigned processes through an asset-light model with Indian contract manufacturers. This approach echoes moves by U.S. startups like Solugen, which secured a conditional Department of Energy loan guarantee for enzyme and electrochemical platforms, and the UK's Chemify, which has raised tens of millions in venture capital and public funding for automated synthesis facilities.
India's specialty chemicals sector saw valuation compression recently, though it retains multi-year potential if companies adopt digital tools and AI to unlock productivity, according to consulting firm analyses. AI uptake in chemicals remains uneven compared to downstream industries, but R&D data leverage and production optimization offer immediate value, industry observers note.
A Crowded Field
NuSynth enters a field where AI-driven retrosynthesis tools have matured rapidly. Merck KGaA's SYNTHIA software, IBM RXN for Chemistry, and MIT's open-source ASKCOS platform offer route prediction and yield optimization. Closer to home, Rasayan Labs, based in San Jose and Nagpur, launched an AI-native computational chemistry platform recently and partnered with eMolecules to link retrosynthetic routes with real-time building-block availability.
Large Indian contract development and manufacturing organizations are investing in related capabilities. Laurus Labs has disclosed investments in flow chemistry, continuous manufacturing, and AI-driven process optimization in recent filings. Other specialty players like Aarti Industries, Deepak Nitrite, SRF, Navin Fluorine International, Gujarat Fluorochemicals, and Clean Science and Technology continue capital expenditures with sustainability in focus, though no partnerships with NuSynth are verified.
Global incumbents are also advancing. China's Asymchem has expanded flow chemistry capabilities internationally. Adani partnered with Dioxycle to scale low-carbon electrochemical manufacturing in India. Chemical & Engineering News, in a feature earlier this year, flagged practical barriers in lab automation that remain unresolved despite AI gains in route prediction: solids handling, end-to-end autonomy, and change management.
The Hard Part Ahead
The regulatory landscape is evolving to support process innovation, though slowly. The International Council for Harmonisation's Q13 guideline on continuous manufacturing, adopted by the FDA in 2023, provides clarity for drug-substance and drug-product makers. India's draft Chemicals (Management and Safety) Rules, colloquially termed "India REACH," remain unpromulgated as of recent months, according to the Ministry of Environment, Forest and Climate Change, but could impose registration and notification requirements once finalized.
NuSynth's thesis aligns with policy priorities and market demand. Whether the startup can scale proprietary routes through its partner network, navigate regulatory complexity, and compete against both established software platforms and vertically integrated CDMOs will determine if India's chemicals sector, sized in the hundreds of billions of dollars, can anchor a new generation of process-innovation companies. The company declined to disclose revenue, customer names, or timelines for commercial production, leaving those benchmarks for later.
For now, NuSynth has capital, partnerships, and a problem worth solving. The chemistry, as it were, remains to be proven.
